Search Results for: current cancer drug target

New Issue :: Current Cancer Drug Targets (Volume: 18, Issue: 7)

  Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and … Continue reading “New Issue :: Current Cancer Drug Targets (Volume: 18, Issue: 7)”

Rate this:

MOST ACCESSED ARTICLE – Multimodal HDAC Inhibitors with Improved Anticancer Activity – Current Cancer Drug Targets

Journal: Current Cancer Drug Targets Author(s): Rainer Schobert, Bernhard Biersack Graphical Abstract:   Abstract: Histone deacetylases (HDACs) play a significant role in the proliferation and dissemination of cancer and represent promising epigenetic drug targets. The HDAC inhibitor vorinostat featuring a zinc-binding hydroxamate fragment was already clinically approved. However, HDAC inhibitors containing hydroxamic acids are often hampered by … Continue reading “MOST ACCESSED ARTICLE – Multimodal HDAC Inhibitors with Improved Anticancer Activity – Current Cancer Drug Targets”

Rate this:

MOST ACCESSED ARTICLE – Multimodal HDAC Inhibitors with Improved Anticancer Activity – Current Cancer Drug Targets

Journal: Current Cancer Drug Targets Author(s): Rainer Schobert, Bernhard Biersack* Graphical Abstract:   Abstract: Histone deacetylases (HDACs) play a significant role in the proliferation and dissemination of cancer and represent promising epigenetic drug targets. The HDAC inhibitor vorinostat featuring a zinc-binding hydroxamate fragment was already clinically approved. However, HDAC inhibitors containing hydroxamic acids are often hampered by acquired … Continue reading “MOST ACCESSED ARTICLE – Multimodal HDAC Inhibitors with Improved Anticancer Activity – Current Cancer Drug Targets”

Rate this:

OPEN ACCESS ARTICLE – HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors – Current Cancer Drug Targets

Journal: Current Cancer Drug Targets Author(s): Sarah L. Sammons, Donna L. Topping, Kimberly L. Blackwell Graphical Abstract:   Abstract: Background: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Objectives: 1. Discuss the mode of action of the … Continue reading “OPEN ACCESS ARTICLE – HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors – Current Cancer Drug Targets”

Rate this:

HIGHLIGHTED ARTICLE – THE COMPLEXITY OF DEK SIGNALING IN CANCER PROGRESSION – CURRENT CANCER DRUG TARGETS

To access the article, please visit: http://www.eurekaselect.com/152617/article

Rate this:

Highlighted Article – Fertility Drugs and Ovarian Cancer – Current Cancer Drug Targets

To access this article, please visit: http://www.eurekaselect.com/153449  

Rate this:

Highlighted Article – Oncolytic Tanapoxvirus Expressing Interleukin-2 is capable if Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells – Current Cancer Drug Targets

http://benthamscience.com/journals/current-cancer-drug-targets/

Rate this:

New Issue :: Current Cancer Drug Targets 17, Issue 7

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and guest edited thematic … Continue reading “New Issue :: Current Cancer Drug Targets 17, Issue 7”

Rate this:

Highlighted Article Flyer for the journal “Current Cancer Drug Targets”

http://benthamscience.com/journals/current-cancer-drug-targets/

Rate this: